Sara C Keller1, Deborah Williams2, Mitra Gavgani2, David Hirsch2, John Adamovich2, Dawn Hohl2, Ayse P Gurses3, Sara E Cosgrove4. 1. Department of Medicine, Division of Infectious Diseases, Johns Hopkins University School of Medicine, Baltimore, Maryland. 2. Johns Hopkins Home Care Group, Baltimore, Maryland. 3. Armstrong Institute of Patient Safety and Quality, Department of Anesthesiology, Baltimore, Maryland. 4. Division of Infectious Diseases, Johns Hopkins University School of Medicine, Baltimore, Maryland.
Abstract
Background: To better monitor patients on outpatient parenteral antimicrobial therapy (OPAT), we need an improved understanding of risk factors for and timing of OPAT-associated adverse drug events (ADEs). Methods: We analyzed a prospective cohort of patients on OPAT discharged from 2 academic medical centers. Patients underwent chart abstraction and a telephone survey. Multivariable analyses estimated adjusted incident rate ratios (aIRR) between clinical and demographic risk factors and clinician-determined clinically significant ADEs. Descriptive data were used to present patient-reported ADEs. Results: Of 339 patients enrolled in the study, 18.0% experienced an ADE (N = 65), of which 49 were significant (14.5%, 2.24/1000 home-OPAT days). Patients with longer courses of therapy had lower rates of ADEs compared with patients treated for 0-13 days (14-27 days: aIRR, 0.44; 95% confidence interval [CI], 0.20-0.99; at least 28 days: aIRR, 0.11; 95% CI, 0.056-0.21). Risk factors for ADEs included female gender and receipt of daptomycin or vancomycin, while treatment for uncomplicated bacteremia and empiric treatment were associated with lower rates of ADEs. Conclusions: OPAT-related ADEs were common and often occurred within 2 weeks of hospital discharge. Patients on OPAT should be monitored more closely for ADEs, including clinical assessment and laboratory monitoring, especially within the first weeks after hospital discharge and particularly among women and patients who receive vancomycin.
Background: To better monitor patients on outpatient parenteral antimicrobial therapy (OPAT), we need an improved understanding of risk factors for and timing of OPAT-associated adverse drug events (ADEs). Methods: We analyzed a prospective cohort of patients on OPAT discharged from 2 academic medical centers. Patients underwent chart abstraction and a telephone survey. Multivariable analyses estimated adjusted incident rate ratios (aIRR) between clinical and demographic risk factors and clinician-determined clinically significant ADEs. Descriptive data were used to present patient-reported ADEs. Results: Of 339 patients enrolled in the study, 18.0% experienced an ADE (N = 65), of which 49 were significant (14.5%, 2.24/1000 home-OPAT days). Patients with longer courses of therapy had lower rates of ADEs compared with patients treated for 0-13 days (14-27 days: aIRR, 0.44; 95% confidence interval [CI], 0.20-0.99; at least 28 days: aIRR, 0.11; 95% CI, 0.056-0.21). Risk factors for ADEs included female gender and receipt of daptomycin or vancomycin, while treatment for uncomplicated bacteremia and empiric treatment were associated with lower rates of ADEs. Conclusions: OPAT-related ADEs were common and often occurred within 2 weeks of hospital discharge. Patients on OPAT should be monitored more closely for ADEs, including clinical assessment and laboratory monitoring, especially within the first weeks after hospital discharge and particularly among women and patients who receive vancomycin.
Authors: Sara C Keller; Danielle Ciuffetelli; Warren Bilker; Anne Norris; Daniel Timko; Alex Rosen; Jennifer S Myers; Janet Hines; Joshua Metlay Journal: J Pharm Technol Date: 2013-10
Authors: Nabin K Shrestha; Pamela Mason; Steven M Gordon; Elizabeth Neuner; Benjamin Nutter; Colin O'Rourke; Susan J Rehm Journal: J Antimicrob Chemother Date: 2014-01-06 Impact factor: 5.790
Authors: Alison M Beieler; Timothy H Dellit; Jeannie D Chan; Shireesha Dhanireddy; Leslie K Enzian; Tamera J Stone; Edward Dwyer-O'Connor; John B Lynch Journal: J Hosp Med Date: 2016-04-27 Impact factor: 2.960
Authors: Philippa C Matthews; Christopher P Conlon; Anthony R Berendt; Jill Kayley; Lorrayne Jefferies; Bridget L Atkins; Ivor Byren Journal: J Antimicrob Chemother Date: 2007-06-11 Impact factor: 5.790
Authors: Michael A Lane; Jonas Marschall; Susan E Beekmann; Philip M Polgreen; Ritu Banerjee; Adam L Hersh; Hilary M Babcock Journal: Infect Control Hosp Epidemiol Date: 2014-05-09 Impact factor: 3.254
Authors: Sara C Keller; Kathryn Dzintars; Lisa A Gorski; Deborah Williams; Sara E Cosgrove Journal: Pharmacotherapy Date: 2018-03-30 Impact factor: 4.705
Authors: Sarah B Doernberg; Thuy Tien Tram Tran; Steven Y C Tong; Mical Paul; Dafna Yahav; Joshua S Davis; Leonard Leibovici; Helen W Boucher; G Ralph Corey; Sara E Cosgrove; Henry F Chambers; Vance G Fowler; Scott R Evans; Thomas L Holland Journal: Clin Infect Dis Date: 2019-05-02 Impact factor: 9.079
Authors: Pranita D Tamma; Anna T Conley; Sara E Cosgrove; Anthony D Harris; Ebbing Lautenbach; Joe Amoah; Edina Avdic; Pam Tolomeo; Jacqueleen Wise; Sonia Subudhi; Jennifer H Han Journal: JAMA Intern Med Date: 2019-03-01 Impact factor: 21.873
Authors: Rachel S Britt; Mary T LaSalvia; Simi Padival; Parth Patel; Christopher McCoy; Monica V Mahoney Journal: Open Forum Infect Dis Date: 2019-11-19 Impact factor: 3.835
Authors: Ann L N Chapman; Sanjay Patel; Carolyne Horner; Helen Green; Achyut Guleri; Sara Hedderwick; Susan Snape; Julie Statham; Elizabeth Wilson; Mark Gilchrist; R Andrew Seaton Journal: JAC Antimicrob Resist Date: 2019-08-26
Authors: Kate S Grattan; Mohamed Mohamed Ali; Seyed M Hosseini-Moghaddam; Hayley J I Gilmour; Gregory P Crunican; Erica Hua; Kelly A Muhsin; Rochelle Johnstone; Lise C Bondy; Megan K Devlin; Sarah Shalhoub; Sameer Elsayed; Michael S Silverman Journal: JAC Antimicrob Resist Date: 2021-01-18